Celltrion signs deal to acquire US biopharmaceutical facility amid tariff risks

Celltrion, Korea's leading biopharmaceutical company, said Tuesday its U.S. subsidiary has signed a deal to acquire a U.S. biopharmaceutical production facility, a move that it said will "eliminate" risks stemming from imminent U.S. tariff hikes. Celltrion USA will take over a production facility from Eli Lilly for 460 billion won ($330 million) and work to complete the deal by the end of this year, the company said in a press release. "This acquisition fundamentally eliminates U.S. tariff risks," Celltrion Chairman Seo Jung-jin said during an online press conference. By securing a local production hub, Celltrion said it has established a one-stop supply chain in the United States that spans the entire drug manufacturing process from production to commercialization. The company plans to invest 700 billion won in the plant, including the acquisition cost, and an additional 700 billion won for expansion. The U.S. facility, located in New Jersey, is a large-scale, U.S. Food and Drug Administration (FDA)-approved drug substance manufacturing site compliant with current good manufacturing pracWeiter zum vollständigen Artikel bei Korea Times Weiter zum vollständigen Artikel bei Korea Times